Keywords
Last Name
Institution

Kristin Zorn

TitleAssociate Professor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentObstetrics & Gynecology, College of Medicine
DivisionOB & GYN Gynecologic Oncology
Address5516 Cancer Institute
4104 Outpatient Circle
Mail Slot # 793
Little Rock AR 72205
Phone501-686-5093
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentGenetics, College of Medicine


    Collapse Overview 
    Collapse overview
    Dr. Kristin Zorn is an Associate Professor and Director for the Division of Gynecologic Oncology in the Department of Obstetrics & Gynecology, and an Associate Professor in the Division of Genetics.Dr. Zorn earned her medical degree from the University of Alabama School of Medicine in Birmingham, AL. She also completed her residency there in obstetrics and gynecology. Following her residency, she was a gynecologic oncology research fellow at the National Cancer Institute in Bethesda, MD. She completed a clinical fellowship in gynecologic oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, OK.Dr. Zorn is certified by the American Board of Obstetrics and Gynecology for both Obstetrics and Gynecology and Gynecologic Oncology, and is a member of several professional groups including American College of Obstetricians and Gynecologists, American Association for Cancer Research, American Society of Clinical Oncology and Society of Gynecologic Oncology.She is the principal investigator for the NRG Oncology Cooperative group at UAMS and also leads the Hereditary Gynecologic Cancer Clinic.


    Collapse Research Funds 
    Collapse research overview
    Dr. Zorn's research focuses in 2 areas. She is the principal investigator for multiple clinical trials through the NRG Oncology cooperative group sponsored by the NCI as well as pharmaceutical company trials. She also focuses on cancer genetics research, particularly related to increased access to genetic counseling and testing to identify high-risk families and help prevent future cancer diagnoses for them.

    Collapse principal investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691. PMID: 28346442.
      View in: PubMed
    2. Hagan TH, Rosenzweig M, Zorn K, van Londen J, Donovan H. Perspectives on Self-Advocacy: Comparing Perceived Uses, Benefits, and Drawbacks Among Survivors and Providers Oncol Nurs Forum. 2017 01 03; 44(1):52-59. PMID: 28060470.
      View in: PubMed
    3. Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S. Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016 Nov 11; 18(1):112. PMID: 27836010.
      View in: PubMed
    4. Boisen MM, Lesnock JL, Richard SD, Beriwal S, Kelley JL, Zorn KK, Edwards RP. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2016 May; 26(4):626-31. PMID: 27051048.
      View in: PubMed
    5. Zorn KK, Annunziata CM. Editorial: Inhibiting PARP as a Strategic Target in Cancer. Front Oncol. 2016; 6:91. PMID: 27148483; PMCID: PMC4831976.
    6. Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016 Feb 09; 18(1):15. PMID: 26857456; PMCID: PMC4746828.
    7. Hall C, Stone RL, Gehlot A, Zorn KK, Burnett AF. Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence. Int J Gynecol Cancer. 2016 Feb; 26(2):313-7. PMID: 26588235.
      View in: PubMed
    8. Taylor SE, Li R, Petschauer JS, Donovan H, O'Neal S, Keeler AW, Zamboni WC, Edwards RP, Zorn KK. Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer. Gynecol Oncol. 2015 Sep; 138(3):548-53. PMID: 26111788.
      View in: PubMed
    9. Berger JL, Smith A, Zorn KK, Sukumvanich P, Olawaiye AB, Kelley J, Krivak TC. Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. Onco Targets Ther. 2014; 7:1409-13. PMID: 25143745; PMCID: PMC4133030.
    10. Taylor SE, Beck TL, Krivak TC, Zorn KK, Kelley JL, Edwards RP. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity. Gynecol Oncol. 2014 Jul; 134(1):68-72. PMID: 24769036.
      View in: PubMed
    11. Smith AL, Sun M, Bhargava R, Stewart NA, Flint MS, Bigbee WL, Krivak TC, Strange MA, Cooper KL, Zorn KK. Proteomic Analysis of Matched Formalin-Fixed, Paraffin-Embedded Specimens in Patients with Advanced Serous Ovarian Carcinoma. Proteomes. 2013 Oct 17; 1(3):240-253. PMID: 28250404.
      View in: PubMed
    12. Engel NJ, Gordon P, Thull DL, Dudley B, Herstine J, Jankowitz RC, Zorn KK. A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer. Fam Cancer. 2012 Sep; 11(3):419-27. PMID: 22644142.
      View in: PubMed
    13. Skaznik-Wikiel ME, Sukumvanich P, Austin RM, Zorn KK, Krivak TC, Edwards RP, Olawaiye AB. Heavy cervical cancer burden in elderly women: how can we improve the situation? Acta Cytol. 2012; 56(4):388-93. PMID: 22846717.
      View in: PubMed
    14. Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD, Lanchbury JS, Krivak TC. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2012 Jun; 125(3):677-82. PMID: 22406760.
      View in: PubMed
    15. Rungruang B, Courtney-Brooks M, Beriwal S, Zorn KK, Richard SD, Olawaiye AB, Krivak TC, Sukumvanich P. Surgery versus radiation therapy for stage IB2 cervical carcinoma: a population-based analysis. Int J Gynecol Cancer. 2012 Mar; 22(3):484-9. PMID: 22249576.
      View in: PubMed
    16. Skaznik-Wikiel ME, Lesnock JL, McBee WC, Beriwal S, Zorn KK, Richard SD, Krivak TC, Edwards RP. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes. Int J Gynecol Cancer. 2012 Feb; 22(2):232-7. PMID: 22080886.
      View in: PubMed
    17. Zorn KK. PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check. Oncology (Williston Park). 2012 Feb; 26(2):128-36. PMID: 22489345.
      View in: PubMed
    18. Skaznik-Wikiel ME, Sukumvanich P, Beriwal S, Zorn KK, Kelley JL, Richard SD, Krivak TC. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. Int J Gynecol Cancer. 2011 Aug; 21(6):1013-7. PMID: 21792011.
      View in: PubMed
    19. Shukla G, Beriwal S, Krivak TC, Kelley JL, Sukumvanich P, Edwards RP, Richard S, Olawaiye A, Zorn KK. Preoperative high dose rate brachytherapy for clinical stage II endometrial carcinoma. J Contemp Brachytherapy. 2011 Jun; 3(2):70-73. PMID: 27895672.
      View in: PubMed
    20. Rungruang B, Hood BL, Sun M, Hoskins E, Conrads TP, Zorn KK. Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome. J Proteome Res. 2010 Nov 05; 9(11):6071-6. PMID: 20873867; PMCID: PMC3190590.
    21. Richard SD, Sukumvanich P, Lesnock JL, McBee WC, Beriwal S, Edwards RP, Zorn KK, Krivak TC. Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):932-5. PMID: 20683398.
      View in: PubMed
    22. Zorn KK. Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment. Oncology (Williston Park). 2010 Jul; 24(8):738, 740. PMID: 20718253.
      View in: PubMed
    23. Gingell D, Samuel A, Haynik D, McBee W, Kelley J, Zorn K, Bhargava R. Metastatic ovarian serous carcinoma presenting as inflammatory breast cancer: a case report. Int J Gynecol Pathol. 2010 May; 29(3):243-7. PMID: 20407323.
      View in: PubMed
    24. Courtney-Brooks M, Sukumvanich P, Beriwal S, Zorn KK, Richard SD, Krivak TC. Does the number of nodes removed impact survival in vulvar cancer patients with node-negative disease? Gynecol Oncol. 2010 May; 117(2):308-11. PMID: 20153883.
      View in: PubMed
    25. Wegner RE, Beriwal S, Heron DE, Richard SD, Kelly JL, Edwards RP, Sukumvanich P, Zorn KK, Krivak TC. Definitive radiation therapy for endometrial cancer in medically inoperable elderly patients. Brachytherapy. 2010 Jul-Sep; 9(3):260-5. PMID: 20122872.
      View in: PubMed
    26. Lesnock JL, Richard SD, Zorn KK, Krivak TC, Beriwal S, Sukumvanich P, McBee WC, Kelley JL, Edwards RP. Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. Gynecol Oncol. 2010 Mar; 116(3):345-50. PMID: 19959211.
      View in: PubMed
    27. Dumrongpakapakorn P, Hopkins K, Sherwood P, Zorn K, Donovan H. Computer-mediated patient education: opportunities and challenges for supporting women with ovarian cancer. Nurs Clin North Am. 2009 Sep; 44(3):339-54. PMID: 19683095; PMCID: PMC3686083.
    28. Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer. 2009 Mar 01; 115(5):1028-35. PMID: 19156927; PMCID: PMC2664510.
    29. Beriwal S, Coon D, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, Zorn KK, Krivak TC. Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma. Gynecol Oncol. 2008 May; 109(2):291-5. PMID: 18455637.
      View in: PubMed
    30. Coon D, Beriwal S, Heron DE, Kelley JL, Edwards RP, Sukumvanich P, Zorn KK, Krivak TC. High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):779-83. PMID: 18258388.
      View in: PubMed
    31. Guirguis A, Elishaev E, Oh SH, Tseng GC, Zorn K, DeLoia JA. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary. Gynecol Oncol. 2008 Feb; 108(2):370-6. PMID: 18083218.
      View in: PubMed
    32. Moore KN, Gold MA, McMeekin DS, Walker JL, Rutledge T, Zorn KK. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol. 2008 Mar; 108(3):466-71. PMID: 18191994.
      View in: PubMed
    33. Dann RB, Kelley JL, Zorn KK. Strategies for ovarian cancer prevention. Obstet Gynecol Clin North Am. 2007 Dec; 34(4):667-86, viii. PMID: 18061863.
      View in: PubMed
    34. Zorn KK. Advancing our understanding of endometrial cancer histologic subtypes: should we lump or split? Gynecol Oncol. 2007 Jul; 106(1):6-7. PMID: 17574072.
      View in: PubMed
    35. Moore KN, Gold MA, McMeekin DS, Zorn KK. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol. 2007 Sep; 106(3):498-501. PMID: 17561235.
      View in: PubMed
    36. Krivak TC, Zorn KK. Venous thromboembolism in obstetrics and gynecology. Obstet Gynecol. 2007 Mar; 109(3):761-77. PMID: 17329532.
      View in: PubMed
    37. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6422-30. PMID: 16166416.
      View in: PubMed
    38. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005 Sep 01; 11(17):6300-10. PMID: 16144934.
      View in: PubMed
    39. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res. 2003 Oct 15; 9(13):4811-8. PMID: 14581352.
      View in: PubMed
    Zorn's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _